Annovis Bio Regains NYSE Listing Compliance, Secures Continued Trading
Annovis Bio Inc. has met NYSE continued listing standards after correcting its market capitalization and stockholders' equity, ensuring its common stock remains listed under ticker ANVS.
Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing therapies for Alzheimer's and Parkinson's diseases, has announced that it has regained compliance with New York Stock Exchange continued listing standards. The company implemented corrective measures to restore its market capitalization and stockholders' equity above required thresholds, allowing its common stock to continue trading on the NYSE under the ticker symbol ANVS.
The announcement is significant for investors and the biotechnology sector, as it removes the risk of delisting that could have hampered the company's ability to raise capital and advance its lead drug candidate, buntanetap. Buntanetap is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer's disease (AD) and Parkinson's disease (PD).
The NYSE listing compliance is a critical milestone for Annovis, as it provides continued access to public capital markets and maintains investor confidence. The company had previously faced challenges meeting the exchange's listing standards, but its corrective actions have now resolved those issues. For more details on the compliance announcement, visit the full press release at https://ibn.fm/XDgif.
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company's mission is to combat the progression of AD and PD by targeting the root causes of neurodegeneration. With buntanetap now in Phase 3 trials, the company is positioned to potentially deliver a novel therapy that could improve outcomes for millions of patients worldwide. For more information about Annovis Bio, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. This development underscores the importance of regulatory compliance for biotech firms and highlights the ongoing efforts of Annovis Bio to advance its pipeline while maintaining a strong public listing. The restoration of NYSE compliance not only secures the company's trading status but also reinforces its credibility in the investment community as it progresses toward potential regulatory approvals.